

FIG. 1

APPROVED	O.G. FIG.	
BY	CLASS	SUBCLASS
DRAFTSMAN		

2/20




FIG. 2

APPROVED	O. G. FIG.	
BY	CLASS	SUBCLASS
DRAFTSMAN		

3/20




FIG. 3




FIG. 4

5/20

EFFECT OF HYB165 AND ITS CONTROL HYB508  
ON A19, PTX10 AND PTX20 OVARIAN CARCINOMA CELL GROWTH




FIG. 5

6/20

EFFECT OF HYB165 AND ITS CONTROL HYB508  
ON A19, PTX10 AND PTX22 OVARIAN CARCINOMA CELL GROWTH




FIG. 6

7/20

EFFECT OF HYB165 AND ITS CONTROL HYB508  
ON A19, PTX10 AND PTX22 OVARIAN CARCINOMA CELL GROWTH




FIG. 7

8/20





FIG. 8



9/20

EFFECT OF HYB165 OR HYB618 ON  
OVCAR-3 OVARIAN CARCINOMA CELL GROWTH




OLIGO CONCENTRATION (μM)

FIG. 9

10/20


ZR-75-1



HYB 165 = 0.1 $\mu$ M (a-d) 0.5 $\mu$ M (e-h)  
 DOCETAXEL = 0.01; 0.03; 0.1; 0.3nM  
 HYB 508 = 0.5 $\mu$ M (i-l)

FIG. 10

ZR-75-1



HYB 165 = 0.1 $\mu$ M (a-d) 0.5 $\mu$ M (e-h)  
DOCETAXEL = 0.01; 0.03; 0.1; 0.3nM  
HYB 508 = 0.5 $\mu$ M (i-l)

FIG. 11

APPROVED	O.G. FIG.	
BY	CLASS	SUBCLASS
DRAFTSMAN		

12/20




FIG. 12




FIG. 13

EFFECT OF HYB165 OR HYB508 ON  
ZR-75.1 BREAST CARCINOMA CELL GROWTH




FIG. 14

EFFECT OF HYB165 AND CONTROL HYB295 ON SOFT AGAR GROWTH  
OF GEO COLON CANCER CELLS




FIG. 15




FIG. 16A



17/20




FIG. 16B




FIG. 17A

19/20




FIG. 17B

TABLE: HISTOCHEMICAL ANALYSIS OF GEO TUMORS FOLLOWING  
TREATMENT WITH TAXOL AND/OR DIFFERENT ORAL MBOs.

	TUMOR SIZE (cm <sup>3</sup> )	Ki67	RI $\alpha$	AR	TGF $\alpha$	p27	VESSELS
CONTROL	1.49	40%	70%	85%	50%	10%	15
TAXOL	0.80	20%	60%	70%	50%	10%	5
HYB165	1.02	28%	35%	50%	20%	15%	3
SCRAMBLE	1.39	30%	60%	85%	50%	8%	14
HYB165 + TAXOL	0.4	6%	15%	25%	30%	25%	0
SCRAMBLE + TAXOL	0.81	28%	60%	70%	50%	8%	7

ANALYSIS WAS PERFORMED AFTER THE 2nd CYCLE OF TREATMENT (ON DAY 27).  
NUMBERS REPRESENT THE PERCENTAGE OF POSITIVE CELL STAINING FOR EACH ANTIGEN.

FIG. 18